Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
The approval marks a significant step forward for Regentis as it prepares to bring GelrinC to patients in Europe. The new manufacturing process not only boosts production capacity but also enhances occupational and environmental safety by eliminating solvents. This could help the company meet potential demand more efficiently and reduce costs, which may be crucial for market penetration.
According to the company, GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available. The implant is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This cell-free, off-the-shelf approach could offer a simpler alternative to existing treatments that require cell harvesting or transplantation.
Regentis is expanding its European Centers of Excellence and surgeon training programs to support commercial launch. The collaboration with Humanitas Research Hospital in Milan underscores the company’s efforts to build clinical evidence and surgeon expertise. The company’s newsroom provides updates on its progress at https://ibn.fm/RGNT.
The U.S. cartilage repair market, valued at approximately $3 billion, represents a substantial opportunity for Regentis. However, the company faces competition from established players and emerging technologies. The European approval for the next-generation manufacturing process could give Regentis a competitive edge by improving supply reliability and cost structure.
Investors should note that forward-looking statements in this article involve risks and uncertainties. Regentis Biomaterials’ filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, detail these risks. The full press release is available at https://ibn.fm/Ths4h.
